Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,298 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment Response Clear all
Completed Not applicable Interventional Results available

Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation

NCT04243798
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 7, 2026, 2:24 PM EST
Completed Phase 2Phase 3 Interventional

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

NCT00097357
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Nov 7, 2026, 2:24 PM EST
Completed Not applicable Interventional

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

NCT03195192
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
biomarker study
Other
Lead sponsor
Side-Out Foundation
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Nov 7, 2026, 2:24 PM EST
Completed Not applicable Interventional Results available

Riluzole in the Treatment of Bipolar Depression

NCT00544544
View directory record Official record
Conditions
Bipolar Depression
Interventions
Riluzole
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Nov 7, 2026, 2:24 PM EST
Completed Phase 3 Interventional Results available

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

NCT00891046
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Louisville, Kentucky • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Nov 7, 2026, 2:24 PM EST
Terminated Phase 2 Interventional

Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

NCT00305383
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Viramidine, Peginterferon alfa-2b
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Los Angeles, California • San Mateo, California • Bradenton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Nov 7, 2026, 2:24 PM EST
Recruiting Phase 2 Interventional

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT06701903
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
ITI-1284 10 mg, ITI-1284 20 mg, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroendocrine Response to Oral Alcohol Administration

NCT03165942
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Alcoholic Beverage, Non-Alcoholic Beverage, Ethanol
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Nov 7, 2026, 2:24 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Glendale, Arizona • Glendale, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 7, 2026, 2:24 PM EST
Completed Not applicable Interventional

A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases

NCT05035420
View directory record Official record
Conditions
COVID-19, Upper Respiratory Infection, Lower Respiratory Infection
Interventions
Fitbit, Douglas Bag, Periflux 6000 EPOS, BIOPAC, Flowmet, NIRS
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 78 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Nov 7, 2026, 2:24 PM EST
Completed Phase 3 Interventional

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

NCT00106288
View directory record Official record
Conditions
Candidiasis
Interventions
Micafungin, Liposomal Amphotericin B
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Nov 7, 2026, 2:24 PM EST
Terminated Phase 4 Interventional Results available

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

NCT04134208
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Fluciclovine F18, Positron Emission Tomography
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Nov 7, 2026, 2:24 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Symptomatology and Treatment Response in Psychotic Major Depression

NCT00691535
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Nov 7, 2026, 2:24 PM EST
Recruiting No phase listed Observational

Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer

NCT07764133
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Not listed
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 7, 2026, 2:24 PM EST
Terminated Phase 3 Interventional Accepts healthy volunteers

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06397768
View directory record Official record
Conditions
RSV Immunization
Interventions
RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 12 Months
Enrollment
2,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 7, 2026, 2:24 PM EST
Terminated Phase 3 Interventional Results available

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

NCT01764997
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Nov 7, 2026, 2:24 PM EST
Completed No phase listed Observational

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

NCT01460641
View directory record Official record
Conditions
Rectal Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Nov 7, 2026, 2:24 PM EST
Active, not recruiting No phase listed Observational

Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool

NCT05311046
View directory record Official record
Conditions
Sepsis
Interventions
Pediatric sepsis screening tool (either algorithmic or manual)
Diagnostic Test
Lead sponsor
Computer Technology Associates, Inc.
Industry
Eligibility
3 Months to 45 Years
Enrollment
12,961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 7, 2026, 2:24 PM EST
Terminated Phase 4 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

NCT01283971
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Nov 7, 2026, 2:24 PM EST
Completed Not applicable Interventional

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

NCT06595030
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Active Lighting Intervention, Control Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Menands, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 7, 2026, 2:24 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Responses to Information on Treatments for Depression

NCT04639765
View directory record Official record
Conditions
Depressive Symptoms
Interventions
CBT without Personalization, CBT with Personalization, ADM without Personalization, ADM with Personalization, Combined Treatment without Personalization, Combined Treatment with Personalization
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 7, 2026, 2:24 PM EST
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

NCT05672927
View directory record Official record
Conditions
Immunization, HPV Infection, Human Papillomavirus
Interventions
9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
27 Years to 45 Years · Female only
Enrollment
618 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 7, 2026, 2:24 PM EST
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

NCT05083286
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Encino, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Nov 7, 2026, 2:24 PM EST
Completed Phase 1 Interventional

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066
View directory record Official record
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 7, 2026, 2:24 PM EST